Fansimef

Author:Prof. Dr. med. Peter Altmeyer

All authors of this article

Last updated on: 29.10.2020

Dieser Artikel auf Deutsch

Requires free registration (medical professionals only)

Please login to access all articles, images, and functions.

Our content is available exclusively to medical professionals. If you have already registered, please login. If you haven't, you can register for free (medical professionals only).


Requires free registration (medical professionals only)

Please complete your registration to access all articles and images.

To gain access, you must complete your registration. You either haven't confirmed your e-mail address or we still need proof that you are a member of the medical profession.

Finish your registration now

DefinitionThis section has been translated automatically.

Antimalaria drug not approved in Germany, combination preparation of mefloquine (250 mg), sulfadoxine (500 mg) and pyrimethamine (25 mg) per tbl.

Half-lifeThis section has been translated automatically.

4–16 h

IndicationThis section has been translated automatically.

Chloroquine-resistant malaria through Pl. falciparum.

Dosage and method of useThis section has been translated automatically.

  • Non-immune adults and adults with > 60 kg bw: 3 tbl/day.
  • Adults < 60 kg KG and children 10-14 years (31-45 kg): 2 tbl/day
  • children 7-9 years (21-30 kg): 1 1/2 dbl/day
  • children 4-6 years (11-20 kg): 1 dbl./day
  • children < 4 years (5-10 kg): 1/2 dbl/day

Undesirable effectsThis section has been translated automatically.

mefloquine, pyrimethamine

InteractionsThis section has been translated automatically.

mefloquine, pyrimethamine

ContraindicationThis section has been translated automatically.

Hypersensitivity to one of the ingredients, blood formation disorders, epilepsy, newborns.

Authors

Last updated on: 29.10.2020

Author: Prof. Dr. med. Peter Altmeyer